Dimethyl Fumarate DR Presolicitation
ID: SPE2D2-21-R-0102Type: Presolicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)
Timeline
    Description

    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.

    Point(s) of Contact
    Files
    Title
    Posted
    The document concerns Solicitation No. SPE2D2-21-R-0102, issued by the Defense Logistics Agency (DLA) for a national contract related to pharmaceutical products, specifically Dimethyl Fumarate in specified dosages. The purpose is to provide a reliable source of these pharmaceutical items for Department of Defense (DoD) customers through the Pharmaceutical Prime Vendor (PPV) program. The contract spans one year, potentially extendable to five years, focusing on ensuring product availability and compliance with government standards. Key points include the contractor's obligations to fulfill orders placed by PPV contractors within stipulated timeframes, the need for compliance with various labeling and packaging requirements, and the establishment of business-to-business agreements with PPV vendors. Delivery must be made within 15 days after receipt of orders, and contractors must notify the DLA of any backorders. Additionally, contractors should be prepared to accept an estimated annual demand and are required to register their products with various drug databases. This Request for Proposal (RFP) emphasizes a structured approach to procuring pharmaceuticals for military healthcare, aiming for efficient distribution, compliance with federal regulations, and maintaining product integrity throughout the supply chain.
    The document serves as an amendment to a solicitation or contract modification, specifically for Golden State Medical Supply Inc., related to contract SPE2D2-23-D-0004. It reflects administrative adjustments, including the exercise of an option for an extension of the contract period from October 28, 2023, to October 27, 2024. The contracting authority emphasizes that all other terms and conditions remain unchanged. Acknowledgment of this amendment is crucial as failure to do so may result in rejection of any submitted offers. The document highlights the importance of compliance with federal procurement processes and ensures that the contractor is informed about the contract continuity and required steps for acknowledgment. Signed by the responsible contracting officer, Jason C. Wray, it underscores the procedural nature of contract management within federal procurement frameworks.
    The document is an amendment to the solicitation/modification of a federal contract numbered SPE2D2-23-D-0004, issued by DLA Troop Support’s Medical Supply Chain. It involves Golden State Medical Supply, Inc., located in Camarillo, California. The purpose of this amendment is to exercise Option 2 of the contract, extending its duration from October 28, 2024, to October 27, 2025. The amendment stipulates that all other terms and conditions of the contract will remain unchanged. Currently, the administering office is identified as SPE2D2, and the modification reflects necessary administrative changes as specified under FAR regulations. The document emphasizes the requirement for the contractor to acknowledge receipt of the amendment and informs them that failure to do so may lead to the rejection of their offer. It is signed by the contracting officer Jason C. Wray, with contact information provided for further inquiries. This modification highlights the continuance of government procurement processes involving medical supplies, ensuring compliance and operational readiness in fulfilling federal obligations.
    This document is an amendment to a federal solicitation, specifically Modification 0001 to Contract ID SPE2D221R0102, issued by DLA Troop Support. The primary purpose of this amendment is to correct key dates related to the solicitation. The solicitation issue date has been revised from July 8, 2021, to August 11, 2021. Additionally, the due date for offers has been updated from August 9, 2021, at 3:00 PM EDT to September 14, 2021, at 3:00 PM EDT. Importantly, all other terms and conditions remain unchanged and in full force. This modification necessitates that contractors acknowledge the receipt of this amendment to ensure compliance with the new deadlines, as failure to do so may result in offer rejection. The document includes guidelines on acknowledging the amendment and clarifies the administrative changes resulting from this modification.
    The document is an amendment to a solicitation related to federal contracts, specifically identified as Amendment 0002 to solicitation SPE2D221R0102. The primary purpose of this amendment is to correct the due date for offer submissions from September 14, 2021, at 9:00 PM EDT to 3:00 PM EDT. It underscores that aside from this modification to the offer due date, all other terms and conditions of the previous document remain intact and operational. Furthermore, it outlines the procedures for contractors to acknowledge the amendment, either through direct communication or by updating their existing offers prior to the new deadline. This amendment serves as a formal notification to potential contractors about the change, ensuring compliance with established procurement processes. Overall, this document reflects standard practices in government Requests for Proposals (RFPs) to ensure clarity and maintain contractual integrity throughout the solicitation process.
    This document serves as an amendment to a federal solicitation regarding Contract ID SPE2D221R0102. The amendment specifies a crucial change: the closing date for offers has been extended from September 14, 2021, to October 14, 2021, at 3:00 PM EST. It emphasizes that all other terms and conditions of the original contract remain unchanged and in full force. The amendment must be acknowledged by contractors, who are required to return a specified number of signed copies to the issuing office. This formal notice is part of the protocol for managing government procurement processes, ensuring that contractors have adequate time to prepare their offers while maintaining compliance with existing guidelines. The amendment is part of standard practices in government contracting, which aim to provide transparency and flexibility in procurement while adhering to regulatory frameworks.
    Lifecycle
    Title
    Type
    Presolicitation
    Similar Opportunities
    Metformin HCL
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Famotidine
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    Pantoprazole DR Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    Lamotrigine
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of various dosages of Lamotrigine ER, a pharmaceutical product. This solicitation (SPE2D2-25-R-0002) outlines the submission procedures for interested contractors, emphasizing the requirement for electronic submissions via the Defense Logistics Agency Internet Bid Board System (DIBBS) by the deadline of January 9, 2025. Lamotrigine is a critical medication used in the treatment of epilepsy and bipolar disorder, making this procurement essential for maintaining adequate supplies for military and healthcare facilities. For further inquiries, interested parties can contact Nancy Fernandez at nancy.fernandez@dla.mil or Jason C. Wray at Jason.Wray@dla.mil.
    Repaglinide
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Repaglinide Tablets. The contract will establish a national supply source for the purchase of Repaglinide 0.5MG, 1MG, and 2MG in 100 count bottles. This acquisition will be unrestricted and fully competitive. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items listed in the schedule will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. Interested parties should contact Phyllis Daraio for any questions/comments. The projected solicitation date is September 2020.
    Rabeprazole Sodium Delayed Release Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Rizatriptan Benzoate
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rizatriptan Benzoate tablets. The contract will establish a national supply source to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on the DLA Bid Board System and SAM.gov. Interested parties should contact Keith Ryales for any questions/comments. The projected solicitation date is June 2022.
    Norgestimate/Ethinyl Estradiol Tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is soliciting offers for the supply of Norgestimate/Ethinyl Estradiol Tablets, a pharmaceutical product essential for oral contraceptive use. The procurement aims to establish a contract that outlines specific supply requirements, estimated quantities for multiple option years, and compliance with federal regulations, including ethical conduct and labor standards. This solicitation is critical for ensuring the availability of these contraceptive medications to support military personnel and their families. Interested contractors must submit their offers via the Defense Logistics Agency Internet Bid Board System (DIBBS) by January 21, 2025, and are encouraged to contact Kyle Lewicki at kyle.lewicki@dla.mil or Jason C. Wray at Jason.Wray@dla.mil for further information.
    Valsartan
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.
    Doxycycline Hyclate Solicitation
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of Doxycycline Hyclate tablets under solicitation number SPE2D2-25-R-0004. This procurement aims to secure pharmaceutical products in various quantities and packaging configurations, with specific requirements outlined for compliance with federal regulations, including business ethics and subcontracting plans. Doxycycline Hyclate is a critical antibiotic used in various medical applications, making this procurement essential for maintaining adequate supplies for military and healthcare operations. Interested contractors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by January 21, 2025, and are encouraged to contact Courtney Hunter-Stangler or Jason C. Wray for further information regarding the solicitation.